Entrada Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Entrada Therapeutics's estimated annual revenue is currently $19.5M per year.
- Entrada Therapeutics's estimated revenue per employee is $92,559
- Entrada Therapeutics's total funding is $175M.
Employee Data
- Entrada Therapeutics has 211 Employees.
- Entrada Therapeutics grew their employee count by 32% last year.
Entrada Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | VP | Head CMC | Reveal Email/Phone |
3 | VP, Program Governance & Portfolio Management | Reveal Email/Phone |
4 | Head Total Rewards & HR Operations | Reveal Email/Phone |
5 | Head Intellectual Property | Reveal Email/Phone |
6 | Director, Quantitative Biology | Reveal Email/Phone |
7 | Chief Medical Officer | Reveal Email/Phone |
8 | Senior Director & Head, Patient Advocacy | Reveal Email/Phone |
9 | Sr. Director, Quality | Head Quality | Reveal Email/Phone |
10 | Associate Director, Bioanalytical Lead | Reveal Email/Phone |
Entrada Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Entrada Therapeutics?
Entrada Therapeuticsￃﾢ￢ﾂﾬ￢ﾄﾢ mission is to treat devastating diseases by developing intracellular biologics. Using its proprietary EEVￃﾢ￢ﾀﾞￂﾢ technology, Entrada is creating a diverse pipeline of enzyme, oligonucleotide, protein and peptide programs to efficiently engage intracellular disease targets across multiple therapeutic areas. The Companyￃﾢ￢ﾂﾬ￢ﾄﾢs novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics. Entrada, a privately-held company, raised $59 million in a Series A financing in December 2018. The financing was co-led by 5AM Ventures and MPM Capital, along with Roche Venture Fund, MRL Ventures Fund and Agent Capital. For more information, please visit www.entradatx.com.
keywords:N/A
$175M
Total Funding
211
Number of Employees
$19.5M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Entrada Therapeutics News
Alstiel is currently a part-time CMO at Pinteon Therapeutics. ... Alaunos Therapeutics, Homology Medicines, Entrada Therapeutics, Enterome,...
Entrada Therapeutics had issued 9,075,000 shares in its initial public offering on October 29th. The total size of the offering was $181,500,000...
Entrada, an intracellular therapeutics company currently located on Tide Street in Boston, is moving just down the street. The company is...
Entrada Therapeutics Inc., a Boston, MA-based biotechnology company dedicated to advancing treatment of devastating diseases using intracellular biologics, closed a $116m Series B financing. The round was led by Wellington Management Company. Wellington Management was joined by Redmile Group, T ...
Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the successful completion of a $116 million Series B financing. The Series B financing was led by Wellington Managemen ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $54.3M | 211 | -24% | N/A |
#2 | $15M | 211 | -2% | N/A |
#3 | $58.3M | 211 | 21% | N/A |
#4 | $29.6M | 212 | -20% | $172M |
#5 | $35M | 212 | 8% | N/A |